Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

A novel series of spirocyclic derivatives was synthesized and evaluated as NPY Y5R antagonists for the treatment of obesity. Cis and trans analogs 7a and 8a were equipotent in a Y5R binding assay (K(i)'s ≤ 1 nM) and displayed good stability in human and rat liver microsome preparations. Compound 7a failed to demonstrate weight loss activity in a diet-induced obese (DIO) rat model at unbound drug levels in the brain that exceeded the Y5R K(i) value by 25-fold over a 24-h time-period.

[1]  M. Ando,et al.  Modulation of neuropeptide Y receptors for the treatment of obesity , 2009, Expert opinion on therapeutic patents.

[2]  M. Heilig,et al.  Diverse functions of neuropeptide Y revealed using genetically modified animals , 2002, Neuropeptides.

[3]  B. S. Hamilton,et al.  The role of NPY in metabolic homeostasis: implications for obesity therapy , 2000, Expert opinion on investigational drugs.

[4]  P. Magni,et al.  Relevance of the neuropeptide Y system in the biology of cancer progression. , 2007, Current topics in medicinal chemistry.

[5]  T. Maurer,et al.  In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist. , 2003, Journal of medicinal chemistry.

[6]  Bengt Långström,et al.  Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. , 2006, Cell metabolism.

[7]  G. Bish,et al.  Practical Synthesis of (1s,4s)-4-(Methylamino)-1′H-spiro[cyclohexane-1,3′-furo[3,4-c]pyridin]-1′-one , 2010 .

[8]  G. Bray,et al.  Effect of NPY5R Antagonist MK‐0557 on Weight Regain after Very‐low‐calorie Diet‐induced Weight Loss , 2007, Obesity.

[9]  H. Iwaasa,et al.  Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist. , 2009, Bioorganic & medicinal chemistry.

[10]  A. Beck‐Sickinger,et al.  Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development , 2011, Journal of peptide science : an official publication of the European Peptide Society.

[11]  Dafydd R Owen,et al.  Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis. , 2009, Bioorganic & medicinal chemistry letters.

[12]  D. Macneil,et al.  A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure , 2007, Molecular Pharmacology.

[13]  D. Macneil,et al.  A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Inui,et al.  Neuropeptide y receptor selective ligands in the treatment of obesity. , 2007, Endocrine reviews.

[15]  H. Iwaasa,et al.  Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[16]  A. M. Stewart,et al.  Synthesis of a Spiro[cyclohex-1,1‘-isobenzofuranyl] Dopamine Receptor Antagonist , 1999 .